[go: up one dir, main page]

SG11202110958QA - Anti-vegf protein compositions and methods for producing the same - Google Patents

Anti-vegf protein compositions and methods for producing the same

Info

Publication number
SG11202110958QA
SG11202110958QA SG11202110958QA SG11202110958QA SG11202110958QA SG 11202110958Q A SG11202110958Q A SG 11202110958QA SG 11202110958Q A SG11202110958Q A SG 11202110958QA SG 11202110958Q A SG11202110958Q A SG 11202110958QA SG 11202110958Q A SG11202110958Q A SG 11202110958QA
Authority
SG
Singapore
Prior art keywords
producing
methods
same
protein compositions
vegf protein
Prior art date
Application number
SG11202110958QA
Inventor
Shawn Lawrence
Amy Johnson
Meghan Casey
Jaimie Mastrogiacomo
Shunhai Wang
Ning Li
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76210828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202110958Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202110958QA publication Critical patent/SG11202110958QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/80—Fraction collectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SG11202110958QA 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same SG11202110958QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06
US202063065012P 2020-08-13 2020-08-13
PCT/US2020/046823 WO2021112924A1 (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Publications (1)

Publication Number Publication Date
SG11202110958QA true SG11202110958QA (en) 2021-10-28

Family

ID=76210828

Family Applications (6)

Application Number Title Priority Date Filing Date
SG11202110968VA SG11202110968VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110964QA SG11202110964QA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110953UA SG11202110953UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110972UA SG11202110972UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110958QA SG11202110958QA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110955VA SG11202110955VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Family Applications Before (4)

Application Number Title Priority Date Filing Date
SG11202110968VA SG11202110968VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110964QA SG11202110964QA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110953UA SG11202110953UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same
SG11202110972UA SG11202110972UA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202110955VA SG11202110955VA (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Country Status (19)

Country Link
US (37) US11186625B2 (en)
EP (11) EP3906302A1 (en)
JP (14) JP2022550930A (en)
KR (13) KR20230051297A (en)
CN (6) CN114423783A (en)
AU (14) AU2020398830C1 (en)
BR (2) BR112021025158A2 (en)
CA (4) CA3159586A1 (en)
CO (6) CO2021018234A2 (en)
IL (18) IL318471A (en)
MX (10) MX2022006759A (en)
MY (12) MY193353A (en)
NZ (6) NZ781145A (en)
PE (6) PE20221770A1 (en)
SG (6) SG11202110968VA (en)
TW (10) TW202509053A (en)
UA (1) UA129709C2 (en)
WO (7) WO2021112929A1 (en)
ZA (5) ZA202107647B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7235770B2 (en) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Formulations Containing High Concentrations of VEGF Receptor Fusion Proteins
KR20210052389A (en) 2018-08-27 2021-05-10 리제너론 파마슈티칼스 인코포레이티드 Use of Raman spectroscopy in downstream purification
CN113227785A (en) * 2019-01-16 2021-08-06 瑞泽恩制药公司 Methods and systems for identifying and quantifying antibody fragmentation
GB201910697D0 (en) * 2019-07-26 2019-09-11 Binding Site Group Ltd Lonisation control
SG11202110968VA (en) * 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
AR127006A1 (en) * 2021-09-08 2023-12-06 Regeneron Pharma A HIGH-PERFORMANCE, MASS SPECTROMETRY-BASED METHOD FOR QUANTIFYING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CA3233420A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process of purification of fusion protein
CN116162148B (en) * 2021-11-24 2025-09-09 中山光度生物医药有限公司 Multispecific ligand binding molecules and uses thereof
US20250223313A1 (en) * 2022-01-14 2025-07-10 Shattuck Labs, Inc. Methods of contaminant removal from protein isolates
CN119278050A (en) * 2022-05-23 2025-01-07 英哈隆生物制药公司 Compositions and methods for inhalable therapeutic agents
CN120322464A (en) * 2022-12-01 2025-07-15 信达生物制药(苏州)有限公司 Tri-specific fusion protein and its use
WO2024148276A1 (en) * 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
KR20240115650A (en) 2023-01-19 2024-07-26 주식회사 스카이테라퓨틱스 An amorphous nano molecule of tyrosine kinase inhibitors and containing composition and method for producing the same
AU2024241785A1 (en) * 2023-03-29 2025-11-13 Cyrus Biotechnology, Inc. Ides variant proteins and methods of using the same
WO2025030053A1 (en) * 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
WO2025227916A1 (en) * 2024-04-29 2025-11-06 齐鲁制药有限公司 Composition comprising aflibercept and variant thereof, related method therefor, and use thereof
US12240888B1 (en) * 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses
WO2025245371A1 (en) * 2024-05-22 2025-11-27 Seismic Therapeutic, Inc. Polypeptides comprising protease-resistant fc domain, compositions and uses thereof

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1522343A (en) 1923-05-02 1925-01-06 Thom Clarence Magnetic separator
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
EP0283942B1 (en) * 1987-03-24 1992-05-20 W.R. Grace & Co.-Conn. Basal nutrient medium for cell culture
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
SE519827C2 (en) 1998-03-30 2003-04-15 Viranative Ab Nutritional medium containing methionine and its use
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
IL146890A0 (en) * 1999-06-08 2002-08-14 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
AU2669501A (en) * 1999-11-30 2001-06-12 Smithkline Beecham Plc New use
MXPA02011534A (en) 2000-05-26 2004-08-12 Bristol Myers Squibb Co Soluble ctla4 mutant molecules and uses thereof.
ATE420945T1 (en) 2001-02-15 2009-01-15 Centocor Inc CHEMICALLY DEFINED MEDIUM FOR CULTURED MAMMAL CELLS
EP1421098A4 (en) 2001-04-13 2006-03-15 Wyeth Corp Surface proteins of streptococcus pyogenes
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8777906B1 (en) 2002-01-24 2014-07-15 Robin Scott Gray Syringe with inspection window
PL377603A1 (en) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN100537751C (en) 2004-05-12 2009-09-09 华东理工大学 The serum free medium that a kind of suitable Chinese hamster ovary cell is cultivated
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CA2585547A1 (en) * 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
DK2586459T3 (en) 2005-03-25 2017-09-11 Regeneron Pharma VEGF antagonist formulations
ATE548049T1 (en) 2005-06-09 2012-03-15 Hansa Medical Ab USE OF IDES PROTEINASE (FROM S. PYOGENES) TO TREAT AUTOIMMUNE DISEASES AND TRANSPLANT REJECTION
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
CN1778903A (en) 2005-09-29 2006-05-31 华东理工大学 A high-density continuous perfusion culture method for animal cells
EP1973942B1 (en) * 2005-12-22 2011-02-09 Genentech, Inc. Recombinant production of heparin binding proteins
DK2522717T3 (en) 2006-01-04 2014-04-22 Baxter Int Oligopeptide-free cell culture media
CN100502945C (en) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Use of VEGF receptor fusion proteins for treating ocular diseases
RU2432155C3 (en) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. VEGF ANTAGONIST COMPOSITIONS SUITABLE FOR INTRAVITREAL INTRODUCTION
PE20081194A1 (en) 2006-07-13 2008-09-22 Wyeth Corp GLYCOPROTEIN PRODUCTION
ZA200900836B (en) * 2006-08-28 2010-05-26 Ares Trading Sa Process for the purification of FC-fusion proteins
KR101603632B1 (en) 2006-09-10 2016-03-16 글리코토페 게엠베하 Use of human cells of myeloid leukaemia origin for expression of antibodies
MX345141B (en) 2006-09-13 2017-01-18 Abbvie Inc * Cell culture improvements.
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
AU2008240080A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
JP2010536355A (en) 2007-08-31 2010-12-02 エフ．ホフマン−ラ ロシュ アーゲー Glycosylation profile analysis
CN101903401B (en) * 2007-12-21 2013-06-05 罗切格利卡特公司 Antibody Stability Test
KR101415099B1 (en) 2008-07-31 2014-07-08 고쿠리츠 다이가쿠 호진 교토 다이가쿠 Molding material containing unsaturated polyester resin and microfibrillated plant fiber
CA2737580A1 (en) 2008-09-26 2010-04-01 Schering Corporation High titer antibody production
AU2010254215A1 (en) 2009-05-26 2011-12-01 Momenta Pharmaceuticals, Inc. Production of glycoproteins
KR20120027055A (en) 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 Readily isolated bispecific antibodies with native immunoglobulin format
KR101574056B1 (en) 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Cell culture medium for adamts protein expression
BR112012009289B8 (en) * 2009-10-20 2021-05-25 Abbott Laboratoires method for purifying an anti-il-13 antibody from a sample mixture comprising an anti-il-13 antibody and at least one host cell protein (hcp)
EP2325296A1 (en) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US8568250B2 (en) * 2010-07-07 2013-10-29 Nike, Inc. Golf ball with cover having zones of hardness
EP3222285A1 (en) 2011-01-13 2017-09-27 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CN102653729B (en) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 Culture medium used for Chinese hamster ovary cells
WO2012140487A1 (en) 2011-04-11 2012-10-18 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
US9670519B2 (en) 2011-04-29 2017-06-06 Biocon Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
EP2702164B8 (en) 2011-04-29 2016-03-16 Biocon Research Limited A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
AU2012203095B2 (en) 2011-05-27 2016-02-04 Abbvie Biotechnology Ltd DAC HYP compositions and methods
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
CN108771655A (en) * 2011-10-28 2018-11-09 诚信生物公司 Protein formulation containing amino acid
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
CN102757496B (en) * 2012-06-07 2014-06-18 山东泉港药业有限公司 Method for purifying and preparing anti-VEGF antibody fragment
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
US9695416B2 (en) * 2012-07-18 2017-07-04 Siemens Healthcare Diagnostics Inc. Method of normalizing biological samples
AR091967A1 (en) * 2012-08-02 2015-03-11 Sanofi Sa MANUFACTURING ARTICLE INCLUDING AFLIBERCEPT OR 2IV-AFLIBERCEPT
BR112015004467A2 (en) 2012-09-02 2017-03-21 Abbvie Inc method for controlling protein heterogeneity
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
EP2722673B1 (en) * 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
US9365314B2 (en) * 2012-11-16 2016-06-14 Owens-Brockway Glass Container Inc. Product and package with a photosensitive use-evident feature
US20140271622A1 (en) 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
CN103146648A (en) 2013-03-14 2013-06-12 北京京蒙高科干细胞技术有限公司 Animal source-free and serum-free culture medium of lymphocyte
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
JP6602746B2 (en) * 2013-03-15 2019-11-06 カポン、ダニエル・ジェイ． Hybrid immunoglobulins containing non-peptidyl bonds
MX360779B (en) 2013-03-15 2018-11-16 Genentech Inc Cell culture compositions with antioxidants and methods for polypeptide production.
CN103773732B (en) 2013-06-08 2016-05-11 李锋 The production technology of definite culture medium, its application and the large-scale culture mammalian cell of a kind of chemical composition
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015058369A1 (en) 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
JP6609561B2 (en) 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド Use of cation exchange chromatography in flow-through mode to enrich post-translational modifications
CN104073464A (en) 2014-07-08 2014-10-01 西藏天虹科技股份有限责任公司 Serum-free CHO cell culture medium and preparation method thereof
AR101262A1 (en) 2014-07-26 2016-12-07 Regeneron Pharma PURIFICATION PLATFORM FOR Bispecific Antibodies
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CA2977675A1 (en) * 2015-03-12 2016-09-15 Medimmune, Llc Method of purifying albumin-fusion proteins
KR101867134B1 (en) * 2015-03-23 2018-06-12 한양대학교 산학협력단 Cell culture media for production of target material with high yield using mammalian cell, method for culturing cells and production of target material using the cell culture media
CN107429227B (en) 2015-04-01 2022-03-01 勃林格殷格翰国际公司 cell culture medium
CN105002242A (en) 2015-07-23 2015-10-28 苏州康聚生物科技有限公司 Serum-free culture medium for efficiently expressing recombinant human thyroid-stimulating hormone in CHO cells and application thereof
TWI797060B (en) 2015-08-04 2023-04-01 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
EP3334842B1 (en) 2015-08-12 2022-03-02 Novartis AG Methods of treating ophthalmic disorders
WO2017069158A1 (en) * 2015-10-22 2017-04-27 プロテノバ株式会社 Immunoglobulin-binding polypeptide
EP3377151A1 (en) 2015-11-18 2018-09-26 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
RU2734958C2 (en) * 2015-11-18 2020-10-26 Формикон Аг Pre-filled pharmaceutical package containing a liquid formulation based on a vegf antagonist
CN105368808B (en) * 2015-11-30 2019-04-30 苏州康聚生物科技有限公司 A kind of IdeS protease, preparation method and application
EP3394102A1 (en) 2015-12-22 2018-10-31 Regeneron Pharmaceuticals, Inc. Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia
PT3394103T (en) 2015-12-22 2023-09-04 Regeneron Pharma COMBINATION OF ANTI-PD-1 ANTIBODIES AND BIESPECIFIC ANTI-CD20/ANTI-CD3 ANTIBODIES TO TREAT CANCER
EP3196646B1 (en) * 2016-01-19 2019-12-18 Hexal AG Methods of mapping protein variants
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
CN107025553A (en) * 2016-01-29 2017-08-08 上海新卡说信息技术有限公司 A kind of transaction processing method and transaction system
US20200283472A1 (en) * 2016-03-29 2020-09-10 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
CN106279412A (en) * 2016-09-12 2017-01-04 广东东阳光药业有限公司 A kind of purification method of anti-VEGF class monoclonal antibody
PL3515946T3 (en) 2016-09-23 2022-11-07 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antibodies
NZ751906A (en) 2016-09-23 2025-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
TWI782930B (en) 2016-11-16 2022-11-11 美商再生元醫藥公司 Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
CN116327963A (en) * 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 Ophthalmic preparation and application thereof
BR112019011900A2 (en) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited improved methods for increasing antibody productivity in mammalian cell culture and minimizing aggregation during downstream processes, formulation processes, and stable antibody formulations obtained from them
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
KR101861163B1 (en) 2017-04-26 2018-05-25 삼천당제약주식회사 Ophthalmic pharmaceutical composition
WO2018215580A1 (en) * 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
ES2887046T3 (en) * 2017-08-17 2021-12-21 Just Evotec Biologics Inc Method of purification of glycosylated protein from host cell galectins and other contaminants
EP3697449A1 (en) * 2017-10-18 2020-08-26 REGENXBIO Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
JP7183268B2 (en) * 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド Aflibercept formulation containing lysine salt as tonicity agent and its use
CN109929038B (en) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Purification method of VEGF (vascular endothelial growth factor) capture agent fusion protein
CN109929027B (en) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Method for purifying recombinant fusion protein by linear elution step
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
JP7235770B2 (en) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Formulations Containing High Concentrations of VEGF Receptor Fusion Proteins
MY209456A (en) * 2018-10-29 2025-07-09 Beijing Res Inst Chemical Ind China Petroleum & Chemical Corp Porous composite material capable of generating electric arc in microwave field, preparation method therefor, and use thereof
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US20220098279A1 (en) 2019-01-30 2022-03-31 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
KR102286892B1 (en) * 2019-07-08 2021-08-06 삼천당제약주식회사 Refining method of ophthalmic protein pharmaceuticals
SG11202110968VA (en) * 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same

Also Published As

Publication number Publication date
US20220048975A1 (en) 2022-02-17
BR112021025158A2 (en) 2022-06-21
KR20220038347A (en) 2022-03-28
KR20220041083A (en) 2022-03-31
US11505593B2 (en) 2022-11-22
AU2023201588A1 (en) 2023-04-13
JP2025114741A (en) 2025-08-05
AU2020396490A1 (en) 2021-10-28
IL288355B (en) 2022-11-01
MY193355A (en) 2022-10-06
MX2023005421A (en) 2023-05-23
CA3172625A1 (en) 2021-06-10
SG11202110953UA (en) 2021-10-28
US20230235019A1 (en) 2023-07-27
MX2022006760A (en) 2023-01-30
TW202509053A (en) 2025-03-01
IL309491B1 (en) 2025-02-01
KR20250053206A (en) 2025-04-21
AU2023201588B2 (en) 2025-06-26
IL309560B2 (en) 2025-05-01
MY193351A (en) 2022-10-06
US11459373B2 (en) 2022-10-04
IL296863B1 (en) 2023-06-01
PE20221791A1 (en) 2022-11-25
US20220033471A1 (en) 2022-02-03
IL288367A (en) 2022-01-01
US12012445B2 (en) 2024-06-18
IL296863B2 (en) 2023-10-01
TW202128744A (en) 2021-08-01
IL304390B2 (en) 2025-05-01
MX2022012042A (en) 2022-10-27
CO2021018214A2 (en) 2022-01-17
CO2021018181A2 (en) 2022-01-17
KR20230051296A (en) 2023-04-17
US20220396608A1 (en) 2022-12-15
CN114206925A (en) 2022-03-18
US11753459B2 (en) 2023-09-12
EP4524237A2 (en) 2025-03-19
NZ781136A (en) 2023-05-26
WO2021112926A1 (en) 2021-06-10
KR20230051297A (en) 2023-04-17
IL296512B2 (en) 2023-12-01
KR20220038062A (en) 2022-03-25
IL288351B2 (en) 2024-05-01
JP2024119936A (en) 2024-09-03
AU2023201748B2 (en) 2025-08-21
IL288367B2 (en) 2023-02-01
BR112021025438A2 (en) 2022-06-21
AU2020398125C1 (en) 2023-05-11
MX2022006759A (en) 2023-01-30
US20250197474A1 (en) 2025-06-19
AU2023201589A1 (en) 2023-04-06
SG11202110964QA (en) 2021-10-28
WO2021112924A1 (en) 2021-06-10
BR112021025359A2 (en) 2022-06-21
IL301888B2 (en) 2025-03-01
AU2023201590B2 (en) 2025-07-03
AU2025242105A1 (en) 2025-10-23
IL288352B2 (en) 2023-03-01
CA3129193C (en) 2022-10-04
EP4524237A3 (en) 2025-07-09
MX2022006788A (en) 2022-07-11
US20230119662A1 (en) 2023-04-20
US11174283B2 (en) 2021-11-16
IL296512B1 (en) 2023-08-01
JP2022547651A (en) 2022-11-15
CA3159586A1 (en) 2021-06-10
US20240309064A1 (en) 2024-09-19
TW202128743A (en) 2021-08-01
US20230272044A1 (en) 2023-08-31
MY193349A (en) 2022-10-06
IL296893B2 (en) 2024-05-01
IL288355B2 (en) 2023-03-01
IL296864A (en) 2022-11-01
IL296893A (en) 2022-12-01
AU2020398830A1 (en) 2021-10-28
MX2023014077A (en) 2023-12-11
ZA202107647B (en) 2022-03-30
MY190623A (en) 2022-04-27
MY193353A (en) 2022-10-06
ZA202107646B (en) 2022-03-30
IL296864B2 (en) 2023-10-01
CN114401994A (en) 2022-04-26
IL288351A (en) 2022-01-01
AU2020397865C1 (en) 2023-04-27
EP4524148A2 (en) 2025-03-19
MY190625A (en) 2022-04-27
US12054533B2 (en) 2024-08-06
AU2023201586A1 (en) 2023-04-13
US20220235116A1 (en) 2022-07-28
MX2021014862A (en) 2022-09-27
JP2022547652A (en) 2022-11-15
US20210171605A1 (en) 2021-06-10
JP2024026116A (en) 2024-02-28
TW202122417A (en) 2021-06-16
US20220127331A1 (en) 2022-04-28
CN114206924A (en) 2022-03-18
AU2020398125A1 (en) 2021-10-28
AU2023201585B2 (en) 2025-08-14
AU2020398547C1 (en) 2023-05-11
MY190626A (en) 2022-04-27
NZ781142A (en) 2023-05-26
AU2020398830C1 (en) 2023-04-27
IL304390A (en) 2023-09-01
JP2023179531A (en) 2023-12-19
US20210206832A1 (en) 2021-07-08
MX2022006758A (en) 2023-01-30
IL288360B2 (en) 2023-09-01
US20210214430A1 (en) 2021-07-15
IL288351B1 (en) 2024-01-01
US20210214733A1 (en) 2021-07-15
AU2020398125B2 (en) 2022-12-15
JP2022548818A (en) 2022-11-22
CN114423783A (en) 2022-04-29
EP3931204A1 (en) 2022-01-05
IL296864B1 (en) 2023-06-01
US11407813B2 (en) 2022-08-09
IL309560A (en) 2024-02-01
KR20240005206A (en) 2024-01-11
US20220033472A1 (en) 2022-02-03
IL302538B1 (en) 2025-02-01
EP4524147A2 (en) 2025-03-19
US20220275054A1 (en) 2022-09-01
PE20221788A1 (en) 2022-11-25
WO2021112925A1 (en) 2021-06-10
JP2023171771A (en) 2023-12-05
PE20221790A1 (en) 2022-11-25
US11505594B2 (en) 2022-11-22
EP4524148A3 (en) 2025-07-23
MY193354A (en) 2022-10-06
US20240067701A1 (en) 2024-02-29
AU2020396490B2 (en) 2022-12-15
IL296512A (en) 2022-11-01
IL301888B1 (en) 2024-11-01
US11958894B2 (en) 2024-04-16
NZ781145A (en) 2023-05-26
WO2021112929A1 (en) 2021-06-10
EP4524236A2 (en) 2025-03-19
AU2023201748A1 (en) 2023-06-01
JP2024009949A (en) 2024-01-23
US20220162289A1 (en) 2022-05-26
AU2020398547B2 (en) 2022-12-22
CN114206914A (en) 2022-03-18
US20210284684A1 (en) 2021-09-16
TW202128991A (en) 2021-08-01
SG11202110955VA (en) 2021-10-28
AU2023201586B2 (en) 2025-08-28
JP2022548197A (en) 2022-11-17
JP7744391B2 (en) 2025-09-25
MY193350A (en) 2022-10-06
SG11202110972UA (en) 2021-10-28
US11104715B2 (en) 2021-08-31
AU2020398830B2 (en) 2022-12-15
CO2021018192A2 (en) 2022-01-17
JP7673311B2 (en) 2025-05-08
PE20221261A1 (en) 2022-08-16
US20240294606A1 (en) 2024-09-05
US11542317B1 (en) 2023-01-03
TW202134256A (en) 2021-09-16
EP3906303A1 (en) 2021-11-10
JP2022550930A (en) 2022-12-06
US11440950B2 (en) 2022-09-13
US20250289868A1 (en) 2025-09-18
EP4516800A2 (en) 2025-03-05
IL309491B2 (en) 2025-06-01
CO2021018234A2 (en) 2022-01-17
IL288360A (en) 2022-01-01
BR112021025432A2 (en) 2022-06-21
AU2020397865A1 (en) 2021-10-28
BR112021025769A2 (en) 2022-04-12
IL302921A (en) 2023-07-01
IL318471A (en) 2025-03-01
EP3931303A1 (en) 2022-01-05
US11098112B2 (en) 2021-08-24
CA3129193A1 (en) 2021-06-10
IL302921B1 (en) 2025-05-01
IL288352B (en) 2022-11-01
IL309560B1 (en) 2025-01-01
AU2020397803A1 (en) 2021-10-28
US20210371501A1 (en) 2021-12-02
IL288357A (en) 2022-01-01
TW202128745A (en) 2021-08-01
AU2025263786A1 (en) 2025-11-27
US20220009999A1 (en) 2022-01-13
US20230357357A1 (en) 2023-11-09
MX2021014863A (en) 2022-09-28
KR102519234B1 (en) 2023-04-10
IL304390B1 (en) 2025-01-01
EP3906302A1 (en) 2021-11-10
UA129709C2 (en) 2025-07-09
ZA202308519B (en) 2025-11-26
NZ781143A (en) 2023-05-26
TWI865587B (en) 2024-12-11
CO2021018203A2 (en) 2022-01-17
JP2022552052A (en) 2022-12-15
US20210206833A1 (en) 2021-07-08
US20210171570A1 (en) 2021-06-10
US11053280B2 (en) 2021-07-06
US12319728B2 (en) 2025-06-03
IL288352A (en) 2022-01-01
AU2020398547A1 (en) 2021-10-28
JP2024009950A (en) 2024-01-23
US12054532B2 (en) 2024-08-06
US11180540B2 (en) 2021-11-23
CO2022000660A2 (en) 2022-01-28
IL317707A (en) 2025-02-01
MY190686A (en) 2022-05-10
PE20221789A1 (en) 2022-11-25
US20250034231A1 (en) 2025-01-30
US12012444B2 (en) 2024-06-18
US12077570B2 (en) 2024-09-03
AU2023201585A1 (en) 2023-04-13
IL296893B1 (en) 2024-01-01
NZ781138A (en) 2023-05-26
US20220389081A1 (en) 2022-12-08
AU2023201589B2 (en) 2025-08-28
US11286290B2 (en) 2022-03-29
US11535663B2 (en) 2022-12-27
IL302921B2 (en) 2025-09-01
IL301888A (en) 2023-06-01
IL288357B (en) 2022-11-01
IL302538B2 (en) 2025-06-01
CA3172631C (en) 2024-01-02
CA3172631A1 (en) 2021-06-10
KR102519236B1 (en) 2023-04-10
SG11202110968VA (en) 2021-10-28
JP7681079B2 (en) 2025-05-21
KR102619866B1 (en) 2024-01-04
TW202525842A (en) 2025-07-01
IL302538A (en) 2023-07-01
US11306135B2 (en) 2022-04-19
KR20240005222A (en) 2024-01-11
KR20220035393A (en) 2022-03-22
BR112022001016A2 (en) 2022-08-16
EP3906250A1 (en) 2021-11-10
US11186625B2 (en) 2021-11-30
EP4524236A3 (en) 2025-07-23
IL288355A (en) 2022-01-01
US11649273B2 (en) 2023-05-16
KR20220038348A (en) 2022-03-28
US11485770B2 (en) 2022-11-01
US12202883B2 (en) 2025-01-21
US12049489B2 (en) 2024-07-30
US12338274B2 (en) 2025-06-24
KR20220038349A (en) 2022-03-28
EP3906249A1 (en) 2021-11-10
KR20240007293A (en) 2024-01-16
US20230068199A1 (en) 2023-03-02
US20220227836A1 (en) 2022-07-21
WO2021112923A1 (en) 2021-06-10
US11459374B2 (en) 2022-10-04
US20220098280A1 (en) 2022-03-31
AU2020397803C1 (en) 2023-05-11
KR102860764B1 (en) 2025-09-19
KR20230152810A (en) 2023-11-03
NZ781137A (en) 2023-05-26
WO2021112928A1 (en) 2021-06-10
ZA202208710B (en) 2024-09-25
IL296863A (en) 2022-11-01
AU2023201590A1 (en) 2023-04-13
US20230331812A1 (en) 2023-10-19
JP2024167326A (en) 2024-12-03
US11548932B2 (en) 2023-01-10
MX2022011973A (en) 2022-11-09
US20230041349A1 (en) 2023-02-09
WO2021112927A1 (en) 2021-06-10
US11732025B2 (en) 2023-08-22
US11098311B2 (en) 2021-08-24
AU2020397865B2 (en) 2022-12-15
CN114206907A (en) 2022-03-18
TW202521567A (en) 2025-06-01
PE20221770A1 (en) 2022-11-11
TWI867028B (en) 2024-12-21
EP4516800A3 (en) 2025-07-09
MY190624A (en) 2022-04-27
IL288360B1 (en) 2023-05-01
US11472861B2 (en) 2022-10-18
TW202521150A (en) 2025-06-01
AU2020397803B2 (en) 2022-12-15
IL309491A (en) 2024-02-01
IL288367B (en) 2022-10-01
US20220227835A1 (en) 2022-07-21
US20220009997A1 (en) 2022-01-13
US20240317835A1 (en) 2024-09-26
US11299532B2 (en) 2022-04-12
MY190627A (en) 2022-04-27
EP4524147A3 (en) 2025-07-23
US20220009998A1 (en) 2022-01-13
AU2020396490C1 (en) 2023-04-27
IL288357B2 (en) 2023-03-01
ZA202107644B (en) 2022-03-30

Similar Documents

Publication Publication Date Title
IL304390A (en) Anti-vegf protein compositions and methods for producing the same
SG11202012004SA (en) Rna-targeting fusion protein compositions and methods for use
IL277797A (en) Methods for making stable protein compositions
EP3849618A4 (en) Compositions and methods for hemoglobin production
GB202017593D0 (en) Compositions and methods and uses relating thereto
IL290331A (en) Rna-targeting ligands, compositions thereof, and methods of making and using the same
IL285489A (en) Producing compositions comprising two or more antibodies
IL286587A (en) D-metyrosine compositions and methods for preparing same
HK40055880A (en) Anti-vegf protein compositions and methods for producing the same
HK40057225A (en) Anti-vegf protein compositions and methods for producing the same
HK40055881A (en) Anti-vegf protein compositions and methods for producing the same
HK40055882A (en) Anti-vegf protein compositions and methods for producing the same
HK40055883A (en) Anti-vegf protein compositions and methods for producing the same
HK40057224A (en) Anti-vegf protein compositions and methods for producing the same
HK40073147A (en) Cardiomyocytes and compositions and methods for producing the same
HK40066588A (en) Optimized vaccine compositions and methods for making the same
AU2021401316A1 (en) Protein compositions and methods for producing and using the same
HK40100724A (en) Protein compositions and methods for producing and using the same
GB2586313B (en) Compositions and methods and uses relating thereto
HK40062932A (en) Methods and compositions for protein sequencing
HK40046593A (en) Compositions and methods comprising anti-nrp2 antibodies
HK40042830A (en) Methods for making stable protein compositions
HK40058304A (en) Compositions and methods for hemoglobin production
HK40050894A (en) Rna-targeting fusion protein compositions and methods for use
EP3638693A4 (en) Immunoglobulin compositions and process for obtaining the same